ELOXX PHARMACEUTICALS, INC. (ELOX)

Every figure this model derived for ELOX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2023-09-30
cash 68,729,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 63,388,000 AssetsCurrent 2026-06-30
current liabilities 16,968,000 LiabilitiesCurrent 2026-06-30
equity 46,420,000 StockholdersEquity 2026-06-30
interest expense 25,000 InterestPaidNet 2025-12-31
ocf -6,327,000 NetCashProvidedByUsedInOperatingActivities 2025-12-31
revenue 0 Revenues 2025-12-31
sbc 235,000 ShareBasedCompensation 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up ELOX on one particular measure came for.

RatioValue
current ratio3.74
current ratio reported3.74
dilution pct228.76
growth cv2.32
interest cover-257.52
revenue growth-100.0
revenue growth per share-100.0

What to be careful about

What this model itself distrusts about ELOX's figures. Written by the derivation as it ran, not added afterwards.